LCB-2853

SKU: orb1709276

Description

LCB-2853 is a potent and selective antagonist of the thromboxane A2/prostaglandin H2 (TP) receptor. It effectively inhibits platelet aggregation and vasoconstriction, making it a valuable research tool for studying thrombosis, cardiovascular diseases, and related pathophysiological processes in both in vitro and in vivo experimental models.

Research Area

Immunology & Inflammation, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 141335-10-6
• MW: 421.94
• Purity: 97.15% (May vary between batches)
• Formula: C₂₁H₂₄ClNO₄S
• SMILES: O=C(O)CC1=CC=C(C=C1)CC2(CNS(=O)(=O)C3=CC=C(Cl)C=C3)CCCC2
• Target: Prostaglandin Receptor,PPAR

Bioactivity

• In Vivo:
  In dog coronary stenosis, LCB 2853 demonstrates high efficacy with an ED50 of 7.2 μg/kg. In rat venous thrombosis induced by venous injury and blood stasis, perfused LCB 2853 reduces thrombus weight in a dose-dependent manner with an ED50 of 220 μg/kg/min. In vivo, LCB 2853 shows an ED50 below 1 mg/kg i.v. against platelet aggregation and vasoconstriction, observed in rat arachidonic acid (AA)-induced thrombocytopenia or U 46619-induced hypertension (ED50 = 0.25 and 0.16 mg/kg) and in AA-induced sudden death in mice (ED50 = 0.44 mg/kg). Additionally, LCB 2853 effectively blocks U 46619-induced bronchoconstriction after i.v. administration (ED50 = 18.4 μg/kg).

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LCB2853, LCB-2853, LCB 2853, TXA2 Receptor, TXA2R

Compound Identifiers

PubChem CID

132347